|Day Low/High||31.75 / 31.94|
|52 Wk Low/High||27.37 / 37.12|
Although the eurozone economy is improving, many stocks remain unloved.
Despite the Vytorin setback, the focus here should be on drugs in development, not products in the market.
Between the volatility, hedge fund collapses and toy recalls, it's better to be a poor American in Scotland.
Animal-health units offer promising growth potential for Pfizer and Schering-Plough.
With the deal for Organon, Fred Hassan puts his transformation plan into overdrive.
The pharma company's still aiming to get on track after a lengthy restatement process.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.